SCHEMBL6615840

SCHEMBL6615840

Cc1cc(Br)ccc1S(=O)(=O)Nc1ccsc1-c1c(F)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 2/20 0.40
SCN5A Q14524 2/20 0.40
SCN8A Q9UQD0 2/20 0.40
CCR2 P41597 5/20 0.40
BRD4 O60885 1/20 0.39
BRD1 O95696 1/20 0.39
BRPF1 P55201 1/20 0.39
BRPF3 Q9ULD4 1/20 0.39
MCL1 Q07820 2/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
HSD11B1 P28845 2/20 0.37
PKM P14618 1/20 0.37
VSIR Q9H7M9 1/20 0.37
NMT1 P30419 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PTGES2 Q9H7Z7 1/20 0.36
ACLY P53396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6611773 0.82 BRD4 (0.39) SCN1ASCN5ASCN8ACCR2BRD4
SCHEMBL6612001 0.80 PFKFB3 (0.41) SCN1ASCN5ASCN8ACCR2MCL1
SCHEMBL2762597 0.78 HSD11B1 (0.48) HSD11B1VSIRPOLB
SCHEMBL5830491 0.78 CA1 (0.41) SCN1ASCN5ASCN8ABRD4BRD1
SCHEMBL5831684 0.76 RXFP1 (0.39) SCN1ASCN5ASCN8ABRD4BRD1
SCHEMBL6612314 0.75 PTGES2 (0.48) CCR2CA2PKMPTGES2ACLY
SCHEMBL6616883 0.72 FFAR4 (0.40) SCN1ASCN5ASCN8ACCR2CA2
SCHEMBL6624056 0.72 PFKFB3 (0.39) SCN1ASCN5ASCN8ACA1CA2
SCHEMBL6611897 0.71 ACLY (0.44) CCR2HSD11B1PKMPTGES2ACLY
SCHEMBL20899649 0.69 HSD11B1 (0.40) SCN1ASCN5ASCN8ACCR2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 SCN1A 510/4885SCN5A 953/4885SCN8A 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.